The company said compounded medications play a role for patients who cannot afford brand-name drugs or who need different dosing
WHO Press Release: The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION) The U.S
Use In-Person Provider: See local doctor or weight loss clinic Get prescription filled locally May cost more but ensures compliance Establish Care Elsewhere: If you spend significant time in another state (vacation home, work travel) May be able to establish care in that state Discuss with provider about feasibility Wait for Expansion: Many telehealth providers are expanding state coverage Sign up for notifications when your state is added Regulatory Changes: Things That Could Change Access: FDA Shortage List: If semaglutide is removed from shortage list, compounding may become restricted Legitimate providers will notify patients of changes Brand-name would remain available State Law Changes: Telehealth regulations evolving rapidly Most changes expand access rather than restrict Monitor state legislation if concerned New Federal Telemedicine Rules: Post-COVID telemedicine regulations still being finalized Generally moving toward expanded access Unlikely to restrict legitimate prescribing Provider Licensing: Interstate medical licensure expanding Makes it easier for providers to serve multiple states Should improve access over time How Providers Handle State Compliance: Legitimate Services: Ensure compliance by: Only connecting patients with providers licensed in their state Partnering with pharmacies licensed to ship to each state Monitoring changing regulations Updating practices to remain compliant Notifying patients of any changes TrimRx maintains compliance across all served states and clearly lists which states can access services through their platform
So, what are the critical steps to ensure a successful mixing process, and how can you avoid common pitfalls
Here are the warning signs you should never ignore
Among new molecules on the horizon for the treatment of overweight and obesity, the most promising appears to be tirzepatide (LY3298176), an incretin mimetic with a dual action targeting both the GLP1 receptor and the glucosedependent insulinotropic polypeptide (GIP) receptor 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 (Figure 2 and Supplementary Figure 1)
